
Loading, please wait...

Loading, please wait...

The management of complex infections requires a dynamic approach to address both pathogen clearance and subsequent tissue regeneration. Recently, researchers developed a programmable core-shell nanoplatform (Z-Lyc@ELP) that provides a robust strategy for sequential infection treatment. By utilizing garlic-derived exosome-like nanovesicles (GELNs), this platform adapts to the shifting pathological environment found in chronic wounds and systemic sepsis.
The Z-Lyc@ELP nanoplatform functions through a hierarchical structural separation. The outer shell contains polymyxin B and immunoregulatory molecules. When these vesicles encounter reactive oxygen species (ROS) at the site of infection, they rapidly release their cargo to remodel the pathogenic microenvironment. Furthermore, as the infection progresses and the lesion becomes more acidic, the ZIF-8 core decomposes. This second wave of intervention releases lycopene and zinc ions, which effectively scavenge excessive ROS. Consequently, this process promotes M2 macrophage polarization, upregulates angiogenic factors, and reactivates intrinsic tissue repair mechanisms.
In vivo studies demonstrate the remarkable potential of this technology. Specifically, the nanoplatform achieved a 98.1% healing rate in infectious burn wounds over 16 days. In sepsis models, the treatment resulted in an 80% survival rate over 10 days. These results highlight how pathology-guided strategies can overcome the limitations of conventional nanotechnology. Because the platform dynamically responds to environmental triggers like pH and oxidative stress, it offers a level of precision previously difficult to achieve in clinical settings.
Garlic-derived exosome-like nanovesicles offer high biocompatibility and natural responsiveness to reactive oxygen species. These traits make them ideal carriers for targeted drug delivery in inflammatory environments like infected wounds.
The core-shell structure allows for hierarchical release. The shell addresses initial pathogen invasion and immune dysfunction. Later, the core targets the recovery phase by scavenging ROS and supporting tissue regeneration as the wound environment changes.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Gao Y et al. Garlic-derived exosome-like nanovesicle core-shell platform for sequential infection treatment and tissue repair. J Nanobiotechnology. 2026 Feb 23. doi: 10.1186/s12951-026-04227-2. PMID: 41731513.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A new Z-Lyc@ELP nanoplatform using garlic exosomes shows 98.1% healing in burn wounds and 80% sepsis survival through sequential therapeutic release....
7 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today